IPP Bureau
Cancer surgeons gather in Delhi to learn new cancer therapies
By IPP Bureau - March 11, 2022
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
Strides receives USFDA approval for Colchicine tablets
By IPP Bureau - March 11, 2022
Colchicine tablets are used for the treatment and prevention of gout. It reduces inflammation which causes pain, swelling and other symptoms of gout
USFDA approves Lupin’s Vigabatrin oral solution
By IPP Bureau - March 11, 2022
The product will be manufactured at Lupin’s facility in Goa, India
Medical devices production under PLI scheme gets off the ground
By IPP Bureau - March 10, 2022
A total of 21 applicants have been approved for 49 products, with the potential to utilize an incentive amount of Rs. 2541 crore
Gufic Biosciences collaborates with Selvax for cancer treatment
By IPP Bureau - March 10, 2022
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
Non-invasive leadless pacemaker implanted in a 60-year-old at Fortis Hospital, Malar
By IPP Bureau - March 10, 2022
The medical team led by Dr. Babu Ezhumalai implanted the dual-chamber leadless pacemaker through a non-surgical procedure successfully
Everlife acquires Research Instruments to boost presence in life science and clinical diagnostics
By IPP Bureau - March 10, 2022
The RI investment comes on the back of three other recently completed transactions in Malaysia and Singapore in the last two months
Insilico Medicine and University of Zurich partner to find therapy for Cystinosis
By IPP Bureau - March 10, 2022
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
Pfizer initiates Phase2/3 study of Paxlovid in pediatric participants
By IPP Bureau - March 10, 2022
Paxlovid is the first oral therapy specifically designed to combat Covid-19 to be evaluated in a pediatric clinical study
Non-hazardous viral inactivation medium for Covid-19 available in Europe
By IPP Bureau - March 10, 2022
Breakthrough formulation helps reduce the risk of exposure using a non-hazardous formulation and leakproof format during transport and processing
Vestige launches nutritional supplement for women
By IPP Bureau - March 10, 2022
It has blended 36 important ingredients for a woman’s health, which has a mix of natural extracts, amino acids, multivitamins and minerals
Artificial retinal device mimics human optical illusions: WPI-MANA
By IPP Bureau - March 10, 2022
The team built a multiple ionic device system, each of which had a lithium cobalt oxide channel arranged on a common lithium phosphorus oxynitride electrolyte
Metropolis Healthcare announces 2nd edition of Healthcare Heroes awards
By IPP Bureau - March 10, 2022
As a part of its CSR initiatives, the ‘Healthcare Heroes of India’ Awards by Metropolis aims to identify and recognize those individuals and institutions in healthcare sector with a strong sense of purpose and commitment towards patient care and who have prioritized it over all other growth parameters
Lupin Diagnostics opens first Reference Lab in East India
By IPP Bureau - March 10, 2022
It is also setting up laboratories in West Bengal, Assam, Bihar, Jharkhand and Orissa to comprehensively cater to the East India region
Molecular Health and researchers prove new approach to anticipate molecular causation
By IPP Bureau - March 10, 2022
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
